These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37000892)

  • 1. Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease.
    Cousins KAQ; Irwin DJ; Chen-Plotkin A; Shaw LM; Arezoumandan S; Lee EB; Wolk DA; Weintraub D; Spindler M; Deik A; Grossman M; Tropea TF
    Ann Clin Transl Neurol; 2023 May; 10(5):802-813. PubMed ID: 37000892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology.
    Cousins KAQ; Arezoumandan S; Shellikeri S; Ohm D; Shaw LM; Grossman M; Wolk D; McMillan CT; Chen-Plotkin A; Lee E; Trojanowski JQ; Zetterberg H; Blennow K; Irwin DJ
    Neurology; 2022 Nov; 99(20):e2303-e2312. PubMed ID: 36041863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant Overlap of α-Synuclein, Amyloid-β, and Phospho-Tau Pathologies in Neuropathological Diagnosis of Lewy-related Pathology: Evidence from China Human Brain Bank.
    Cong C; Zhang W; Qian X; Qiu W; Ma C
    J Alzheimers Dis; 2021; 80(1):447-458. PubMed ID: 33554920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
    Coughlin D; Xie SX; Liang M; Williams A; Peterson C; Weintraub D; McMillan CT; Wolk DA; Akhtar RS; Hurtig HI; Branch Coslett H; Hamilton RH; Siderowf AD; Duda JE; Rascovsky K; Lee EB; Lee VM; Grossman M; Trojanowski JQ; Irwin DJ
    Ann Neurol; 2019 Feb; 85(2):259-271. PubMed ID: 30549331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
    Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
    Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-synuclein in the pathophysiology of Alzheimer's disease.
    Twohig D; Nielsen HM
    Mol Neurodegener; 2019 Jun; 14(1):23. PubMed ID: 31186026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels.
    Murray ME; Moloney CM; Kouri N; Syrjanen JA; Matchett BJ; Rothberg DM; Tranovich JF; Sirmans TNH; Wiste HJ; Boon BDC; Nguyen AT; Reichard RR; Dickson DW; Lowe VJ; Dage JL; Petersen RC; Jack CR; Knopman DS; Vemuri P; Graff-Radford J; Mielke MM
    Mol Neurodegener; 2022 Dec; 17(1):85. PubMed ID: 36575455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change.
    Smirnov DS; Ashton NJ; Blennow K; Zetterberg H; Simrén J; Lantero-Rodriguez J; Karikari TK; Hiniker A; Rissman RA; Salmon DP; Galasko D
    Acta Neuropathol; 2022 Apr; 143(4):487-503. PubMed ID: 35195758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease.
    Snellman A; Ekblad LL; Ashton NJ; Karikari TK; Lantero-Rodriguez J; Pietilä E; Koivumäki M; Helin S; Karrasch M; Zetterberg H; Blennow K; Rinne JO
    Neurobiol Dis; 2023 Jul; 183():106175. PubMed ID: 37268240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Mechanisms of the Roles of α-Synuclein, Amyloid-β, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics.
    Noguchi-Shinohara M; Ono K
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
    Twohig D; Rodriguez-Vieitez E; Sando SB; Berge G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; Patra K; Bu G; Benzinger TLS; Karch CM; Fagan A; Morris JC; Bateman RJ; Nordberg A; White LR; Nielsen HM;
    Acta Neuropathol Commun; 2018 Nov; 6(1):130. PubMed ID: 30477568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma biomarkers for prediction of Alzheimer's disease neuropathologic change.
    Bermudez C; Graff-Radford J; Syrjanen JA; Stricker NH; Algeciras-Schimnich A; Kouri N; Kremers WK; Petersen RC; Jack CR; Knopman DS; Dickson DW; Nguyen AT; Reichard RR; Murray ME; Mielke MM; Vemuri P
    Acta Neuropathol; 2023 Jul; 146(1):13-29. PubMed ID: 37269398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
    Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
    JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts.
    Walker L; McAleese KE; Johnson M; Khundakar AA; Erskine D; Thomas AJ; McKeith IG; Attems J
    J Neural Transm (Vienna); 2017 Jun; 124(6):671-683. PubMed ID: 28265813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration.
    Chai YL; Chong JR; Weng J; Howlett D; Halsey A; Lee JH; Attems J; Aarsland D; Francis PT; Chen CP; Lai MKP
    Brain Pathol; 2019 Jan; 29(1):63-74. PubMed ID: 30051532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
    Chatterjee P; Pedrini S; Ashton NJ; Tegg M; Goozee K; Singh AK; Karikari TK; Simrén J; Vanmechelen E; Armstrong NJ; Hone E; Asih PR; Taddei K; Doré V; Villemagne VL; Sohrabi HR; Zetterberg H; Masters CL; Blennow K; Martins RN
    Alzheimers Dement; 2022 Jun; 18(6):1141-1154. PubMed ID: 34494715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms.
    Winkel I; Ermann N; Żelwetro A; Sambor B; Mroczko B; Kornhuber J; Paradowski B; Lewczuk P
    J Neural Transm (Vienna); 2021 Jun; 128(6):817-825. PubMed ID: 34036433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.
    Walker L; McAleese KE; Thomas AJ; Johnson M; Martin-Ruiz C; Parker C; Colloby SJ; Jellinger K; Attems J
    Acta Neuropathol; 2015 May; 129(5):729-48. PubMed ID: 25758940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
    Sierra M; Gelpi E; Martí MJ; Compta Y
    Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.